A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function
Status:
Completed
Trial end date:
2019-04-22
Target enrollment:
Participant gender:
Summary
Two-part Phase 1 study to assess the effect of single therapeutic and supra-therapeutic doses
of lucerastat on the QT/QTc interval duration in healthy subjects (Part A: Pilot study; Part
B: TQT study)
Phase:
Phase 1
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.
Treatments:
1-Deoxynojirimycin Moxifloxacin Norgestimate, ethinyl estradiol drug combination